Organization | Aichi Medical University

Aichi Medical University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Nagakute Japan (1971)

Organization Overview

First Clinical Trial

2003

NCT00093665

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Aichi Cancer Center | Aichi Cancer Center Hospital, Japan | Department of Breast Oncology, Aichi Cancer Center

Active Ingredients

Drugs in Phase 3 Trials (12)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (2 trials)

docetaxel (taxotere) (2 trials)

eribulin (halaven) (1 trial)

fluorouracil (efudex) (2 trials)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

levoleucovorin (fusilev) (1 trial)

paclitaxel (taxol) (1 trial)

pertuzumab (perjeta) (1 trial)

trastuzumab (herceptin) (2 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (3)

cisplatin (platinol) (1 trial)

olaparib (lynparza) (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

mogamulizumab (poteligeo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Digestive System Neoplasms (Phase 3)

Gastrointestinal Neoplasms (Phase 3)

Head and Neck Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 3)

Nasopharyngeal Carcinoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Recurrence (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 16